Olympian Clinical Research

MAY 6, 2024

These targeted therapies revolutionized treatment, offering relief to severe cases by specifically addressing the underlying immune responses causing the disease. If you or someone you know is struggling with plaque psoriasis, consider contacting Olympian Clinical Research.

Treatment 52

Treatment Small Molecule Immune Response Clinical Research 52

Drug Discovery World

OCTOBER 21, 2022

The last month has seen a number of leaps in our understanding of difficult to treat and treatment resistant breast cancers, so here are Drug Discovery World’s top 5 research breakthroughs. In a scientific first, researchers at Penn State successfully 3D bioprinted breast cancer tumours and treated them.

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

Vial

DECEMBER 11, 2023

In the decades since its identification in 1989, advances in clinical research for new Hepatitis C therapies and the introduction of direct-acting antiviral agents (DAAs) have led to viral eradication in more than 98% of patients, resulting in HCV crossing from manageable to being the first curable , chronic viral infection.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required.

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59

RNA Immune Response DNA Molecular Biology 59

The Premier Consulting Blog

APRIL 18, 2024

This is due to the high-risk nature of these kinds of products (especially for a first-in-class therapy) and the fact that some cell or gene therapies can only be administered once due to the development of immune responses to the drug product. Does it have input and buy-in from regulatory agencies?

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Executive Vice President, Research, Gilead Sciences. “The Executive Vice President, Research, Gilead Sciences.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

APRIL 22, 2023

While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation. Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Drug Discovery World

APRIL 15, 2023

The American Association for Cancer Research (AACR) Annual Meeting is taking place at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023. Tuesday, April 18, 2023, 9:00-12:30am ET 7. Tuesday, April 18, 2023, 1:30-5:00pm ET 8.

Virus 130

Virus Clinical Trials Trials Therapies 130

Drug Discovery World

FEBRUARY 5, 2024

Here, experts weigh in on what to expect from cancer research and immunotherapies. To promote the immune response, the posology of biologics is usually high and requires intravenous injection, which raises safety concerns and significantly reduces patient compliance.

Research 290

Research Small Molecule Clinical Trials Immune Response 290

Dark Matter Blog

JULY 16, 2021

Growing up in Shrewsbury, Massachusetts, it was natural for me to attempt to get a summer job up the road at the Worcester Foundation for Biomedical Research, where the first oral contraceptive was created. I am now at the end of a career that has comprised nearly 10 years of academic research and 35 years in biotechnology.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

LifeSciVC

MARCH 1, 2023

Luke, all with the UPMC Hillman Cancer Center at the University of Pittsburgh, summarized the challenges previously encountered in targeting costimulatory pathways and the compelling scientific rationale for targeting CBL-B as a master regulator of the immune system that is downstream of proven mechanisms like CD28, CTLA4 and PD1.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

JANUARY 17, 2021

It was co-sponsored by Merck and Bayer, conducted with the scientific oversight of the Canadian VIGOUR Centre and the Duke Clinical Research Institute. By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses. Aurinia Pharmaceutical’s Voclosporin for Lupus Nephritis.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

OCTOBER 27, 2020

Mirati Therapeutics is a San Diego -based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer. About Mirati Therapeutics.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

Drug Discovery World

AUGUST 2, 2023

PPT1 inhibitors for the treatment of patients with cancer Contemplating the potential of PPT1 inhibition in cancer led to the development of small molecules with high PPT1 affinity and limited toxicity for clinical drug development. Therein is an accessible molecular cavity, sufficiently large to accommodate many small molecules 4.

Small Molecule 130

Small Molecule Immune Response Clinical Trials International 130

The Pharma Data

OCTOBER 27, 2020

AavantiBio’s strategic partnership with University of Florida’s Powell Gene Therapy Center provide their foundational research in rare genetic disorders. Primmune aims to advance the development of their novel orally-administered, small molecule toll-like receptor 7 agonists as therapeutic-adjuvants for acute viral diseases and cancer.

Small Molecule 52

Small Molecule Immune Response Pharmacokinetics Clinical Development 52

NIH Director's Blog: Drug Development

MAY 21, 2020

In a recent paper in the journal Science , researchers used blood drawn from a COVID-19 survivor to identify a pair of previously unknown antibodies that specifically block SARS-CoV-2 from attaching to human cells [2]. They were then able to produce many identical copies of each antibody, referred to as monoclonal antibodies.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

PerkinElmer

NOVEMBER 9, 2022

Immunotherapy has revolutionized cancer treatment and proved to be pivotal in the field of oncological research. These cells overexpress PD-L1, leading to inhibition of cytotoxic T-cells by binding to the PD-1 receptor on activated T-cells, and subsequent evasion of an immune response.

Small Molecule 52

Small Molecule Research Immune Response FDA Approval 52

Drug Discovery World

SEPTEMBER 6, 2022

However, researchers have been working to devise improved and scalable manufacturing processes that meet regulatory scrutiny, and continued dialogue with regulatory authorities throughout the development process to de-risk programs and platforms early and often will shape how successful these processes will be this year.”?

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

JULY 8, 2024

Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University, explores the rise of RNA therapeutics. Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University. And Dorothy W.

RNA 147

RNA Small Molecule Vaccine FDA Approval 147

Drug Target Review

OCTOBER 4, 2023

The research community pressed on, turning to novel compounds that were substantially more potent than those used in the first generation. Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. Dual cytotoxic payload ADCs could address the inherent heterogeneity in tumours.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

AUGUST 20, 2020

T cell immune responses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

SEPTEMBER 9, 2020

During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

Drug Target Review

JULY 7, 2023

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. This can create an abnormal immune response that attacks the cells of our bodies and contributes to the development of autoantibody diseases.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

DECEMBER 11, 2020

The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. Pfizer has a 171-year track record of researching, developing, manufacturing and delivering innovative medicines and vaccines to patients in need.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Agency IQ

JUNE 9, 2023

However, this guideline is primarily intended to provide recommendations on evaluating the immune system’s response to small molecule drugs. The guidance contains recommendations for small molecule drugs, as well as any biological products that fall within CDER’s purview.

FDA 40

FDA Science Small Molecule Immune Response 40

Drug Discovery World

OCTOBER 17, 2023

BN : Expression analysis and imaging-based analyses have indeed been performed by completely separate groups of researchers so far, with little to no interaction between them. Spatial omics offers a new way of understanding these systems by providing a holistic view of healthy and diseased cells, pathogens, and the immune response.

Disease 130

Disease Small Molecule Drugs RNA 130

The Pharma Data

DECEMBER 10, 2020

Senior Vice President and Head of Vaccine Research & Development, Pfizer. “As The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. Jansen, Ph.D.,

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

The Pharma Data

DECEMBER 27, 2020

Reporting encouraging preliminary Phase 1 clinical study results with VAC2 for the treatment of non-small cell lung cancer with high levels of antigen-specific immunogenicity observed.

Therapies 52

Therapies Production Clinical Trials Treatment 52

Drug Discovery World

FEBRUARY 2, 2023

A variation on the master of none vs master of one theme is a single drug that targets several diseases (hence, master of many) but only inhibits a few targets; in the case of the small molecule known as RRx-001, those targets are subject to change depending on the local environmental conditions that are present in certain tissues or cells.

Small Molecule 130

Small Molecule Clinical Trials Disease Therapies 130

The Pharma Data

MAY 7, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

JULY 21, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. Procedures should be in place to avoid injury from fainting. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 6, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Headquartered in Cambridge, Mass.,

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Drug Discovery World

APRIL 12, 2023

Testing new modality drugs poses additional challenges The drug development pipeline is no longer predominantly composed of small molecule drugs. Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the western world 4.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130